Recruiting nowN/AAges 18 Years and up
Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy
Sponsor: Centre Antoine Lacassagne · NCT06029218 on ClinicalTrials.gov ↗
Conditions studied
ChordomaChondrosarcomaEwing SarcomaOsteosarcoma
What it tests
- Proteus ONE one daily beamradiation
- Proteus ONE two daily beamradiation
Where it's running1 site
1 international site
- Recruiting now
Centre Antoine lacassagne
Nice, France 06000
- BONDIAU Pierre Yves(contact)[email protected]
See the official eligibility language
Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.
Inclusion Criteria: * Chordoma, chondrosarcoma of the skull base and spine, Ewing's sarcoma, and osteosarcoma meeting the criteria for treatment by proton therapy * Tumour requiring 2 beams * MRI less than one month old * PS 0-2. * Patient who has read the patient information note and signed the consent form. * Patient with healthcare insurance cover. * Age over 18 years. * For women of childbearing age, negative urine pregnancy test and effective contraception in place for the duration of treatment and for six months following the end of treatment. Exclusion Criteria: * Persons deprived of their liberty or under guardianship. * Unable to undergo the medical follow-up of the clinical investigation for geographical, social or psychological reasons. * Patient eligible for symptom reduction surgery Vulnerable populations and participants defined in Articles 64 to 68 of Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017.
Updated 2024-09-25 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.